证券代码：688247 证券简称：宣泰医药 公告编号：2026-009 上海宣泰医药科技股份有限公司 2025年度业绩快报公告 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 本报告期，公司实现营业总收入44,649.88万元，同比下降12.73%；归属于母公司所有者的净利润为 4,894.63万元，同比下降61.67%，归属于母公司所有者的扣除非经常性损益的净利润为3,137.69万元， 同比下降72.47%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以上海宣泰医药 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 币种：人民币 （二）主要财务数据和指标增减变动幅度达3 ...

智通财经APP讯，宣泰医药(688247.SH)发布2025年度业绩快报，报告期，公司实现营业总收入 44,649.88万元，同比下降12.73%;归属于母公司所有者的净利润为4894.63万元，同比下降61.67%。 主要原因系：(1)报告期内，国家组织第十批药品集采开始执行，公司产品泊沙康唑肠溶片虽未中选本 次集采，但在集采带来的整体市场价格下行压力下，价格也随之下降，产品利润同比下降;(2)在美国市 场，受获批仿制药厂家增加及关税上升等因素影响，美沙拉秦肠溶片销售额与盈利水平同比下降;(3)公 司基于谨慎性原则，按照《企业会计准则》的相关规定，对相关的应收账款、存货、商誉等计提了减值 损失，对当期净利润产生了负面影响。 ...

主要原因系：(1)报告期内，国家组织第十批药品集采开始执行，公司产品泊沙康唑肠溶片虽未中选本 次集采，但在集采带来的整体市场价格下行压力下，价格也随之下降，产品利润同比下降;(2)在美国市 场，受获批仿制药厂家增加及关税上升等因素影响，美沙拉秦肠溶片销售额与盈利水平同比下降;(3)公 司基于谨慎性原则，按照《企业会计准则》的相关规定，对相关的应收账款、存货、商誉等计提了减值 损失，对当期净利润产生了负面影响。 宣泰医药(688247.SH)发布2025年度业绩快报，报告期，公司实现营业总收入44,649.88万元，同比下降 12.73%;归属于母公司所有者的净利润为4894.63万元，同比下降61.67%。 ...

Core Viewpoint - The company, Kew Flower Pharmaceutical (葵花药业), is committed to a distinctive research and development strategy focusing on specific areas such as elderly care, pediatrics, and women's health, with plans to achieve multiple R&D milestones by 2025 [1] Group 1: R&D Strategy - The company adheres to a "buy, modify, connect, and research" strategy to enhance its product pipeline [1] - Continuous and long-term investments are made in targeted areas to enrich the product line [1] Group 2: Product Development - By 2025, the company expects to obtain drug registration certificates for several products, including Ibuprofen Suspension Drops, Polyethylene Glycol 3350 Powder, and others [1] - The company is expanding its portfolio in the elderly pain management sector through collaborative R&D projects [1] - The company has acquired production licenses and related technologies for several drugs, further enhancing its product categories [1] Group 3: Market Position - Multiple applications for drug and health product registration have been accepted, indicating a proactive approach to market expansion [1]

在"买"与"改"层面，公司持续推进小儿肺热咳喘口服液用于儿童急性支气管炎的应用研究，并于2025年 10月获临床试验批准；葵花药业旗下全资子公司拟受让美沙拉秦肠溶片上市许可及相关生产技术，进一 步丰富消化系统疾病治疗领域的产品储备。 随着数字经济蓬勃发展和健康消费持续升级，医药即时零售已从补充渠道演进为行业重要基础设施，即 时零售正成为医药行业新的确定性增长渠道。为此，葵花药业积极拓展销售渠道，探索新营销场景，在 新零售领域的布局取得了阶段性进展。 2025年，葵花药业深耕电商渠道，实现传统电商、社交电商、兴趣电商产品全覆盖，完成平台大药房、 品牌旗舰店的店铺全布局。公司全品类产品在美团买药、京东、淘宝都获得双位数的增长，在渠道结构 优化方面取得了实质性突破。日前，葵花药业还与美团买药、淘宝闪购、京东秒送签署战略合作协议， 宣布共同探索医药即时零售新模式。 与此同时，葵花药业坚定推进"买、改、联、研"组合研发策略，在新产品上取得一系列进展。 自主研发层面，公司洛芬混悬滴剂、聚乙二醇3350散、复方聚乙二醇（3350）电解质散相继获得药品注 册证书，逐步完善消化及呼吸系统产品线；双醋瑞因胶囊、维生素K1滴剂、克 ...

Group 1 - Shengxin Lithium Energy plans to acquire 30% equity of Qicheng Mining for 2.08 billion yuan, aiming to hold 100% of Qicheng Mining post-transaction [1] - Qicheng Mining holds a 70.97% stake in Huirong Mining, which has confirmed Li2O resources of 989,600 tons with an average grade of 1.62% [1] - The acquisition is part of Shengxin Lithium Energy's strategy to enhance its lithium resource portfolio [1] Group 2 - Zhongju High-tech intends to repurchase shares worth 300 million to 600 million yuan, with a maximum price of 26 yuan per share [2] - Baili Tianheng plans to repurchase shares valued between 100 million to 200 million yuan, with a maximum price of 546 yuan per share [3] Group 3 - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for approximately 264 million yuan [5] - Yilake Co. will be included in the consolidated financial statements of China Aluminum post-acquisition [5] Group 4 - Salt Lake Co. intends to acquire 51% of Wuku Salt Lake for 4.605 billion yuan, aiming to become the controlling shareholder [6] - The acquisition is part of Salt Lake Co.'s strategy to accelerate the development of a world-class salt lake industry base [6] Group 5 - Cobalt Co. plans to invest 1.741 billion yuan in the expansion of a lead-zinc mining project with an annual capacity of 1.65 million tons [7] - The investment aims to enhance the mining capacity of the Cobalt Co.'s subsidiary [7] Group 6 - Tianyuan Co. is investing 1.483 billion yuan in a new chlorination titanium dioxide project with an annual capacity of 100,000 tons [9] - The project is part of Tianyuan Co.'s expansion strategy in the titanium dioxide market [9] Group 7 - Jiangbo Long plans to purchase the remaining 19% equity of its subsidiary Zilia Eletrônicos for approximately 46.08 million USD [26] - The acquisition aims to strengthen Jiangbo Long's position in the storage business and expand its international investment layout [26] Group 8 - China National Airlines intends to purchase 60 Airbus A320NEO series aircraft at a total catalog price of approximately 9.53 billion USD [33] - The aircraft are scheduled for delivery between 2028 and 2032 [33]

格隆汇12月30日丨立方制药(003020.SZ)公布，公司拟向鹿灵葵花转让所持有的"美沙拉秦肠溶片（规 格：0.5g）"药品上市许可持有人（简称"持有人"或"MAH"）及相关权益。立方制药合法持有"美沙拉秦 肠溶片（规格：0.5g）"的药品批准文号。经交易双方协商一致，标的产品转让的总费用为3,400.00万元 （含税）。双方确认该金额已充分考虑了标的产品权益的实际价值及市场行情等因素。 ...

格隆汇12月30日｜立方制药(003020.SZ)公告称，公司与葵花药业集团佳木斯鹿灵制药有限公司签订 《美沙拉秦肠溶片MAH转让合同》，拟以3400万元转让所持有的美沙拉秦肠溶片药品上市许可持有人 及相关权益。本次交易不构成关联交易，不构成重大资产重组，尚需国家药品监督管理局审批。转让完 成后，公司将在未来两年内继续为受让方提供该产品的委托生产服务。 ...

立方制药公告，公司与葵花药业集团佳木斯鹿灵制药有限公司签订了《美沙拉秦肠溶片MAH转让合 同》，决定以3400万元转让美沙拉秦肠溶片药品的所有权。 ...

Core Viewpoint - The company has demonstrated significant progress in its high-end generic drug and CRO/CMO businesses, achieving substantial revenue growth and regulatory approvals for key products in both domestic and international markets [1][2][3] Financial Performance - For the first three quarters of 2025, the company reported a revenue of 331 million yuan and a net profit attributable to shareholders of 63.46 million yuan [1] - In Q3 2025, the company achieved a revenue of 112 million yuan and a net profit of 17.88 million yuan [1] - R&D expenses reached 17.19 million yuan in Q3, accounting for 15.36% of total revenue, reflecting the company's commitment to innovation [2] Product Development and Approvals - The company received approval for new specifications of its Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration in September 2025, enhancing its product matrix in the diabetes sector [1] - In October 2025, the same product received tentative approval from the FDA, marking a significant milestone in the company's internationalization efforts [1] - The company’s Tofacitinib Citrate Extended-Release Tablets 11mg specification received formal approval from the FDA in October [2] - The company’s Olaparib Tablets are expected to be selected in the recent national drug centralized procurement, which will help expand sales and market share [2] R&D and Innovation Strategy - The company focuses on a "first-to-market" strategy in high-end generics, achieving multiple first-generic breakthroughs globally [2] - The company has developed three proprietary R&D technology platforms: "Poorly Soluble Drug Solubilization Technology," "Controlled Release Drug Formulation R&D Platform," and "Fixed-Dose Combination Formulation R&D Platform" [2] - The first self-developed modified new drug project, XT-0043, has shown excellent safety and efficacy in Phase II clinical trials [2] CRO/CMO Business Development - The company leverages its dual-platform in China and the U.S. and multiple GMP certifications to deepen collaborations with domestic and international innovative drug companies [3] - The company has advanced over 100 innovative drug formulation development projects and has established a stable CMO production service model for several successfully launched innovative drugs [3] Future Outlook - The company plans to continue its innovation-driven strategy and steadily advance its international layout, focusing on enhancing its high-end generic and modified new drug pipelines [3] - The controlling shareholder has committed not to reduce its stake in the company for two years starting from August 25, 2025, reflecting confidence in the company's long-term development [3]